Navigation Links
Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million
Date:8/19/2007

p> Depreciation and

amortization 29,591 37,069 60,864 70,232

Allowance and provision 398 - 664 -

Total operating expenses 690,730 497,807 1,348,725 661,461

Operating loss (616,988) (497,001) (1,136,660) (657,042)

Interest expenses - net (276,146) (28,913) (401,904) (53,317)

Minority interest in a

subsidiary's loss 750 - 6,921 -

Loss from continuing

operations (892,384) (525,914) (1,531,643) (710,359)

Loss on discontinued

operations:

Discontinued urea

entrepot trade -

Commission paid

to a related party (414,509) - (414,509) -

Net loss $(1,306,893) $(525,914) $(1,946,152) $(710,359)

Other comprehensive

income (loss):

Translation

adjustment (37,337) 9,556 (161,131) 16,197

Comprehensive loss $(1,344,230) $(516,358) $(2,107,283) $(694,162)

Net loss from continuing

operations per common

share - basic and diluted $(0.0120) $(0.0085) $(0.0210) $(0.0118)

Net loss on discontinued

operations per common

share - basic and diluted $(0.0056) $- $(0.0057) $-

Weighted average

number of common shares

outstanding - basic and

diluted 74,157,432 61,598,567 72,971,896 60,423,775

Kiwa Bio-Tech Products Group Corporation

Consolidated Balance Sheet

Item June 30, 2007 December 31, 2006

(unaudited) (audited)

ASSETS

Current assets

Cash and cash equivalents $208,229 $498,103

Accounts receivable, net of bad

<
'/>"/>
SOURCE Kiwa Bio-Tech Products Group Corporation

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Industry Veterans take a look back from 2025: Bio-Technology, and Bio-Informatics are the focus
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports stronger earnings and revenues
4. Third Waves revenues rebound
5. Electronic signs for municipalities: Las Vegas or lost revenues?
6. TDS restates years of revenues, shows slight profit drop
7. Standard Networks reports 125% growth in software revenues
8. Catalyst International profit exceeds expectations
9. New report says Wisconsin R&D spending exceeding expectations
10. Submissions to the Gov.s Business Plan Contest Exceed Expectations
11. Venture Investors early-stage fund grows to $115 million

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...wire/ -- Spectrum Blue Steel is emerging as one of... planet. Through the efforts of True Green Energy ...ing Specialist Leroy Johnston, who has been in the... Spectrum Blue Steel is light years ahead of every...ngs because of the bi products recovered by using ...
(Date:12/2/2009)...wswire/ -- Nearly 600 medical research executives,...ened to explore novel development approaches and i...tnering for Cures meeting. ,, FasterCures, ...e, convened Partnering for Cures to facilitate m...ific discovery into an accessible therapy. This e...
(Date:12/2/2009)... , - "Bolstering Biodiver...,, Coinciding with the International Year o...c is hosting an international conference in Librev...al resources in Africa. The,conference will be att...scientific experts, private companies, representat...
(Date:12/2/2009)...e/ -- S*BIO Pte Ltd today announced data presentat...The American Society of Hematology 51st Annual Mee...l be presented on the clinical results from the Ph...s safety, tolerability and pharmacokinetic/pharmac...om 100 to 600 mg. These doses were administered on...
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...8 ,Neurobiological Technologies, Inc. (NTI(R)) (Na...il 1, 2008, Matthew M. Loar has been appointed Chi...e Company,s headquarters in,Emeryville. Mr. Loar j...ved,as Chief Financial Officer since 2006., "Matt...ficer, and we,will look to his expertise to help g...
...Solutions Holdings PLC,("Plethora", AIM: PLE), the...t and management of urological disorders, today an...t financing agreement with Paul Capital,Healthcare... to $28 million,in cash with $15 million payable u... commercial sale of PSD502 (PLE,s development stag...
... Rx,Corporation (OTC Bulletin Board: PMQC, PMQCU, ...cy services, announced today that it has postponed...lts and discuss 2008 outlook,that was originally s...onal,details about the timing of the 2007 financia...ce call will be forthcoming shortly., About Chem ...
Other Biology Technology:Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 2Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 2Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 4Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results 2
(Date:12/4/2009)...electroencephalogram (EEG) is widely used by physi...o diagnose neurological disorders. However, it has...n the head give an exact view of what is happening...stitute for Biological Cybernetics in Tbingen, Ger...tivity generated within the brain to that measured...
(Date:12/4/2009)...major discovery is challenging accepted thinking a...ated with diseases such as Alzheimer,s and Parkins...rapeutics. , It was believed that amyloid fibril...imes known as fibres - are inert, but that there m...n damage cells and cause disease. , But in a pa...
(Date:12/3/2009)...r ability to learn new information and adapt to ch...in lifelong memories, appears to lie in the minute...g to a new study by NYU Langone Medicine Center re... in the journal Nature . , The scientists, led...iology and neuroscience at NYU School of Medicine,...
Breaking Biology News(10 mins):How to read brain activity? 2New therapy targets for amyloid disease 2Lifelong memories linked to stable nerve connections 2Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 1Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 2Sokolove Law Launches Chinese Drywall Consumer Advocacy Hotline 51037 1Sokolove Law Launches Chinese Drywall Consumer Advocacy Hotline 51037 2Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 51032 1Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 51032 2
...dicine researchers have discovered how new neurons...o regions of the brain where they can replace old ...cell therapies can be specifically targeted to bra...or by stroke. , Associate Professor Qun-Yong Zhou ...ent of Pharmacology have identified a protein that...
...ton University in St. Louis has shown that for som...exual organs, and actually choose them for mating.... sex organ, called a gonopodium. These fish out-co... environment because they have a faster burst spee...ut because the size of their organ slows them down...
... world are breathing a sigh of relief, as they no ...atural disease-fighting substances. Scientists rec...emnii, which lives symbiotically inside the sea sq...compounds that may one day be used in cancer treat...uld not successfully cultivate Prochloron in the l...
Other Biology News:Researchers discover stem cell 'guide' that may be key for targeting neural stem cell treatments 2Certain fish have a special mating preference 2Certain fish have a special mating preference 3Certain fish have a special mating preference 4
Stat-Pack Aldolase Controls from Caldon Biotech, Inc.
EDTA, 0.5 M solution from GE Healthcare, formerly Amersham Biosciences
Human VEGFR2 (KDR), phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Mouse sTNF RII / TNFRSF1B from R&D Systems
Biology Products: